Quantifying metamorphopsia in patients with diabetic macular oedema and other macular abnormalities.

Abstract

PURPOSE:

To quantify subjective visual metamorphopsia in newly diagnosed patients suffering from diabetic macular oedema (DME) and other macular abnormalities and to evaluate anti-VEGF treatment effect.

METHODS:

Patients with DME, subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or retinal venous occlusion (RVO) were recruited. Metamorphopsia score (Mscore) was calculated using M-Charts at baseline and at the end of a series of anti-VEGF injections.

RESULTS:

Fifteen eyes of 10 patients with DME, 14 eyes of 13 patients with AMD-CNV and five patients with RVO were included in this study. At baseline, positive Mscore was observed in 46.6% of eyes with DME, 50% of eyes with AMD-CNV and four of five eyes with RVO. Treatment led to a complete metamorphopsia reduction (Mscore = 0) in 71.4% of DME patients, 35.7% of AMD and 0% of RVO patients.

CONCLUSION:

We suggest that the M-charts may serve as an additional test for diagnosis and follow-up, complementary to morphological evaluation by imaging, in diabetic patients facing their first anti-VEGF treatment.

• Authors: Asaf Achiron, Oded Lagstein, Mirit Glick, Zvi Gur, Elisha Bartov, Zvia Burgansky-Eliash
• Journal: Acta ophthalmologica (Acta Ophthalmol) Vol. 93 Issue 8 Pg. e649-53 (Dec 2015) ISSN: 1755-3768 [Electronic] England
• PMID: 25899144 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2015 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Chemical References

• Angiogenesis Inhibitors
• VEGFA protein, human
• Vascular Endothelial Growth Factor A

Topics

• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (therapeutic use)
• Diabetic Retinopathy (diagnosis, drug therapy, physiopathology)
• Female
• Humans
• Intravitreal Injections
• Macular Edema (diagnosis, drug therapy, physiopathology)
• Male
• Middle Aged
• Retinal Vein Occlusion (diagnosis, drug therapy, physiopathology)
• Tomography, Optical Coherence
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Vision Disorders (diagnosis, drug therapy, physiopathology)
• Visual Acuity (physiology)
• Visual Field Tests
• Visual Fields
• Wet Macular Degeneration (diagnosis, drug therapy, physiopathology)